董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Anders Ullman | 男 | Non-Executive Director | 69 | 16.39万美元 | 未持股 | 2025-10-07 |
| Benjamin Lucas | -- | Principal Executive Officer and Director | -- | 未披露 | 未持股 | 2025-10-07 |
| Ebru Can Temucin | -- | Principal Financial Officer, Principal Accounting Officer and Director | -- | 未披露 | 未持股 | 2025-10-07 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kathleen Rickard | 女 | Chief Medical Officer | 66 | 396.61万美元 | 未持股 | 2025-10-07 |
| Andrew Fisher | 男 | General Counsel | 55 | 未披露 | 未持股 | 2025-10-07 |
| Benjamin Lucas | -- | Principal Executive Officer and Director | -- | 未披露 | 未持股 | 2025-10-07 |
| Ebru Can Temucin | -- | Principal Financial Officer, Principal Accounting Officer and Director | -- | 未披露 | 未持股 | 2025-10-07 |
| Mark W. Hahn | 男 | Chief Financial Officer | 62 | 1845.48万美元 | 未持股 | 2025-10-07 |
董事简历
中英对照 | 中文 | 英文- Anders Ullman
-
Anders Ullman自2015年9月起担任董事会非执行董事。从2015年9月至2018年12月，Ullman博士担任瑞典萨尔格伦斯卡大学医院慢性阻塞性肺疾病“COPD”中心负责人。2013年至2014年，他担任梦百合公司百特国际有限公司（Baxalta Inc.）生物科学业务部门的执行Vice President和研究与开发主管。从2007年到2013年，Ullman博士担任Nycomed Pharma Private Limited（现为武田制药有限公司（Takeda Pharmaceuticals Company Limited）的研究与开发主管Vice President，在那里他领导了用于防止COPD恶化的PDE4抑制剂Daxas的开发和批准。职业生涯早期，他曾担任AstraZeneca公司的多种职务。Ullman博士于2016年1月至2018年5月担任PEXA AB（一家开发和商业化呼吸医学技术的公司）的董事会成员。Ullman博士在哥德堡大学（University of Gothenburg）获得临床药理学的医学博士学位和博士学位。
Anders Ullman,served as Head of R&D and Chief Medical Officer of Swedish Orphan Biovitrum AB ("Sobi"). Mr. Ullman has served on the board of directors of Sobi since May 2019. From September 2015 to December 2018, Dr. Ullman served as Head of the Chronic Obstructive Pulmonary Disease Centre at Sahlgrenska University Hospital, Sweden. From 2013 to 2014, he was Executive Vice President and Head of Research and Development in the BioScience business unit of Baxter International Inc., a healthcare company, which became Baxalta Inc. From 2007 to 2013, Dr. Ullman was Executive Vice President, Head of Research and Development at Nycomed Pharma Private Limited (now part of Takeda Pharmaceuticals Company Limited), where he led the development and approval of Daxas, the PDE4 inhibitor Verona Pharma Plc ed to prevent COPD exacerbations. Earlier in his career, he held a number of roles in AstraZeneca. Dr. Ullman served on the board of directors of Pexa AB, a company that develops and commercializes respiratory medicine technology, from January 2016 to May 2018. Dr. Ullman received a M.D. and a Ph.D. in clinical pharmacology from the University of Gothenburg. - Anders Ullman自2015年9月起担任董事会非执行董事。从2015年9月至2018年12月，Ullman博士担任瑞典萨尔格伦斯卡大学医院慢性阻塞性肺疾病“COPD”中心负责人。2013年至2014年，他担任梦百合公司百特国际有限公司（Baxalta Inc.）生物科学业务部门的执行Vice President和研究与开发主管。从2007年到2013年，Ullman博士担任Nycomed Pharma Private Limited（现为武田制药有限公司（Takeda Pharmaceuticals Company Limited）的研究与开发主管Vice President，在那里他领导了用于防止COPD恶化的PDE4抑制剂Daxas的开发和批准。职业生涯早期，他曾担任AstraZeneca公司的多种职务。Ullman博士于2016年1月至2018年5月担任PEXA AB（一家开发和商业化呼吸医学技术的公司）的董事会成员。Ullman博士在哥德堡大学（University of Gothenburg）获得临床药理学的医学博士学位和博士学位。
- Anders Ullman,served as Head of R&D and Chief Medical Officer of Swedish Orphan Biovitrum AB ("Sobi"). Mr. Ullman has served on the board of directors of Sobi since May 2019. From September 2015 to December 2018, Dr. Ullman served as Head of the Chronic Obstructive Pulmonary Disease Centre at Sahlgrenska University Hospital, Sweden. From 2013 to 2014, he was Executive Vice President and Head of Research and Development in the BioScience business unit of Baxter International Inc., a healthcare company, which became Baxalta Inc. From 2007 to 2013, Dr. Ullman was Executive Vice President, Head of Research and Development at Nycomed Pharma Private Limited (now part of Takeda Pharmaceuticals Company Limited), where he led the development and approval of Daxas, the PDE4 inhibitor Verona Pharma Plc ed to prevent COPD exacerbations. Earlier in his career, he held a number of roles in AstraZeneca. Dr. Ullman served on the board of directors of Pexa AB, a company that develops and commercializes respiratory medicine technology, from January 2016 to May 2018. Dr. Ullman received a M.D. and a Ph.D. in clinical pharmacology from the University of Gothenburg.
- Benjamin Lucas
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Ebru Can Temucin
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
高管简历
中英对照 | 中文 | 英文- Kathleen Rickard
Kathleen Rickard自2019年2月起担任我们的首席医疗官。在加入Verona Pharma之前，Rickard博士曾在医疗诊断产品公司Aerocrine AB担任多个职位，包括2011年4月至2019年1月担任首席医疗官，2014年4月至2019年1月担任首席合规官。任职Aerocrine公司之前，Rickard博士曾Vice President制药公司葛兰素史克（GlaxoSmithKline）呼吸系统药物开发中心的临床开发和医疗事务，并在过去15年中担任葛兰素史克全球呼吸系统专营权临床开发方面的多个其他领导职务。Rickard博士在费城Hahnemann University Hospital获得医学博士学位。
Kathleen Rickard,served in multiple roles at Aerocrine AB, a medical diagnostics product company, including as Chief Medical Officer from 2011 to January 2019, and as Chief Compliance Officer from 2014 to 2019. Prior to Aerocrine, Dr. Rickard was Vice President Clinical Development and Medical Affairs of the Respiratory Medicines Development Centre at GlaxoSmithKline, a pharmaceutical company, and, over a period of 15 years, held a number of other leadership positions in clinical development across GlaxoSmithKline's global respiratory franchise. Dr. Rickard received an M.D. from Hahnemann University Hospital, Philadelphia.- Kathleen Rickard自2019年2月起担任我们的首席医疗官。在加入Verona Pharma之前，Rickard博士曾在医疗诊断产品公司Aerocrine AB担任多个职位，包括2011年4月至2019年1月担任首席医疗官，2014年4月至2019年1月担任首席合规官。任职Aerocrine公司之前，Rickard博士曾Vice President制药公司葛兰素史克（GlaxoSmithKline）呼吸系统药物开发中心的临床开发和医疗事务，并在过去15年中担任葛兰素史克全球呼吸系统专营权临床开发方面的多个其他领导职务。Rickard博士在费城Hahnemann University Hospital获得医学博士学位。
- Kathleen Rickard,served in multiple roles at Aerocrine AB, a medical diagnostics product company, including as Chief Medical Officer from 2011 to January 2019, and as Chief Compliance Officer from 2014 to 2019. Prior to Aerocrine, Dr. Rickard was Vice President Clinical Development and Medical Affairs of the Respiratory Medicines Development Centre at GlaxoSmithKline, a pharmaceutical company, and, over a period of 15 years, held a number of other leadership positions in clinical development across GlaxoSmithKline's global respiratory franchise. Dr. Rickard received an M.D. from Hahnemann University Hospital, Philadelphia.
- Andrew Fisher
Andrew Fisher，创立并领导了一家咨询事务所Andrew Fisher LLC，自2019年9月起专注于为初创公司提供战略建议。此前，从2001年到2018年，他在United Therapeutics Corporation担任过多个职务，包括执行副总裁、首席战略官和副总法律顾问，负责监督各种知识产权、诉讼、合规、风险管理以及投资者和媒体关系事务等。费希尔先生获得了密歇根大学的学士学位和乔治华盛顿大学的法学博士学位。
Andrew Fisher,founded and led a consulting practice, Andrew Fisher LLC, where he focused on providing strategic advice to start-up companies since September 2019. Previously, from 2001 until 2018, he held various roles at United Therapeutics Corporation, including Executive Vice President, Chief Strategy Officer and Deputy General Counsel, where he oversaw a variety of intellectual property, litigation, compliance, risk management, and investor and media relations matters, among other things. Mr. Fisher received a B.A. from the University of Michigan and a J.D. from George Washington University.- Andrew Fisher，创立并领导了一家咨询事务所Andrew Fisher LLC，自2019年9月起专注于为初创公司提供战略建议。此前，从2001年到2018年，他在United Therapeutics Corporation担任过多个职务，包括执行副总裁、首席战略官和副总法律顾问，负责监督各种知识产权、诉讼、合规、风险管理以及投资者和媒体关系事务等。费希尔先生获得了密歇根大学的学士学位和乔治华盛顿大学的法学博士学位。
- Andrew Fisher,founded and led a consulting practice, Andrew Fisher LLC, where he focused on providing strategic advice to start-up companies since September 2019. Previously, from 2001 until 2018, he held various roles at United Therapeutics Corporation, including Executive Vice President, Chief Strategy Officer and Deputy General Counsel, where he oversaw a variety of intellectual property, litigation, compliance, risk management, and investor and media relations matters, among other things. Mr. Fisher received a B.A. from the University of Michigan and a J.D. from George Washington University.
- Benjamin Lucas
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Ebru Can Temucin
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Mark W. Hahn
Mark W. Hahn， 2010年2月，担任公司的执行副总裁和首席财务官。2008年至2009年，他担任Athenix Corp.的首席财务官 。这是一家农业生物技术公司。2010年，他促成了该公司与Bayer CropScience的合并， 并担任公司财务总监。2007年至2008年，他在多家公司担任首席财务官，其中包括一家名为GigaBeam Corporation的电信设备公司。2002年至2007年，他在BuildLinks, Inc.（软件公司）担任财务总监。2001年至2002年，他在PerformaWorks（软件公司）担任财务总监。1996年至2001年，他在Charles & Colvard, Ltd（消费产品公司）担任财务总监。1984 年至1996年，他在安永会计师事务所（ Ernst & Young）及其前身公司担任过多种职务，最后他担任该公司的高级经理。他在威斯康星大学密尔沃基校区活动了会计学和金融学学士学位。他是北卡莱罗纳州和马里兰州的一名注册会计师。
Mark W. Hahn,From January 2018 until its acquisition by Swedish Orphan Biovitrum for up to $915 million in November 2019, Mr. Hahn served as CFO of Dova Pharmaceuticals, a company developing therapeutics for rare diseases. Previously, from 2010 until its acquisition by Melinta Therapeutics in 2017, Mr. Hahn was CFO of Cempra, Inc. Mr. Hahn served on the board of directors of ALSP Orchid Acquisition Corporation I from November 2021 to November 2023. Mr. Hahn received a B.B.A. degree in Accounting and Finance from the University of Wisconsin-Milwaukee and is a Certified Public Accountant in Maryland and North Carolina.- Mark W. Hahn， 2010年2月，担任公司的执行副总裁和首席财务官。2008年至2009年，他担任Athenix Corp.的首席财务官 。这是一家农业生物技术公司。2010年，他促成了该公司与Bayer CropScience的合并， 并担任公司财务总监。2007年至2008年，他在多家公司担任首席财务官，其中包括一家名为GigaBeam Corporation的电信设备公司。2002年至2007年，他在BuildLinks, Inc.（软件公司）担任财务总监。2001年至2002年，他在PerformaWorks（软件公司）担任财务总监。1996年至2001年，他在Charles & Colvard, Ltd（消费产品公司）担任财务总监。1984 年至1996年，他在安永会计师事务所（ Ernst & Young）及其前身公司担任过多种职务，最后他担任该公司的高级经理。他在威斯康星大学密尔沃基校区活动了会计学和金融学学士学位。他是北卡莱罗纳州和马里兰州的一名注册会计师。
- Mark W. Hahn,From January 2018 until its acquisition by Swedish Orphan Biovitrum for up to $915 million in November 2019, Mr. Hahn served as CFO of Dova Pharmaceuticals, a company developing therapeutics for rare diseases. Previously, from 2010 until its acquisition by Melinta Therapeutics in 2017, Mr. Hahn was CFO of Cempra, Inc. Mr. Hahn served on the board of directors of ALSP Orchid Acquisition Corporation I from November 2021 to November 2023. Mr. Hahn received a B.B.A. degree in Accounting and Finance from the University of Wisconsin-Milwaukee and is a Certified Public Accountant in Maryland and North Carolina.